TGTX: Next Biotech to Soar?


+251% in realized profits for me yesterday. If volume picks up in markets today, I’ll be challenging myself to match that number trading securities on which Stifel, Nicolaus & Company, Incorporated is currently doing due diligence.

Ticker Code Ticker Name Ticker Industry Price Change Average Volume (50)*
TTNP Titan Pharmaceuticals, Inc. common stock Biotechnology 14.81% 10,710,521
IBIO Ibio Inc Biotechnology 23.19% 14,024,336
FREQ Frequency Therapeutics Inc Biotechnology 8.20% 130,220
OMER Omeros Corporation Biotechnology 9.54% 525,628
SLS Sellas Life Sciences Group Inc Biotechnology 46.44% 195,907
TBLT Toughbuilt Industries Inc Tools & Accessories -14.96% 3,635,946
HSITF Hadasit Bio Holding Ltd. Biological products, except diagnostic 0.00% OTC – 3
TGTX TG Therapeutics Inc common stock Biotechnology 52.76% 2,708,097
PYPL Paypal Holdings Inc Credit Services 36.57% 10,416,053
CSCO Cisco Systems, Inc. Communication Equipment 13.49% 23,792,304
NFLX Netflix Inc Entertainment 16.12% 9,551,464
HTBX Heat Biologics Inc Biotechnology 24.00% 6,522,272
TTOO T2 Biosystems Inc Diagnostics & Research 4.41% 9,532,221
SRNE Sorrento Therapeutics Inc Biotechnology 67.72% 35,548,290
SQ Square Inc Software – Infrastructure 36.15% 15,618,337
BW Babcock & Wilcox Enterprises Inc Specialty Industrial Machinery 49.00% 489,760
BABA Alibaba Group Holding Ltd – ADR Internet Retail 10.29% 18,188,810
HD Home Depot Inc Home Improvement Retail 21.61% 5,728,792
ADMP Adamis Pharmaceuticals Corp Drug Manufacturers – Specialty & Generic 23.40% 1,958,790
MT ArcelorMittal SA Banks – Diversified 0.43% 6,624,858

Every sector in the stock market has leaders and laggards. Oftentimes, many companies quietly rise from being a fair-to-middling stock to one that is perceived as“the next big thing” in its respective sector.

I think I’ve found one of those today, suspecting the company’s recent news and financial professional sentiment are indicative of the company’s future, at least in the short-term.

TG Therapeutics (NYSE: TGTX) isn’t a heavily traded name such as Gilead or Pfizer, but in recent weeks TGTX has doubled in price-per-share, received two upgrades, and announced positive preclinical data on a cancer drug it’s testing.

Now why are financial institutions taking a look at the company and maybe even making moves on it? We don’t know for sure, but maybe TGTX could be next in line to test a COVID-19 vaccine, or maybe the company announces more positive data on its new cancer drug.

Either way, Wall Street views positive data reported by biotech companies as bullish much more often than not, and sometimes even if a company’s long-term prosperity is questionable, its price can still surge in the short-term. We just saw an example of that yesterday with INO!

Now for the fun part… How I want to trade TGTX alongside Wall Street’s brightest minds today or in the days ahead.

TGTX is forming a classic stair-stepper pattern, which is a bullish trend. Currently trading right above $20/share support, should the stock rise and markets make a red-to-green move, this stock does indeed have room to run toward $25/share.

The path of least resistance for this stock is to the upside – there isn’t much of a bearish trading opportunity on TGTX today. The stock is also in a clear uptrend as indicated by the chart above – unless that changes, I don’t want to bet against this trend!

I’ll be looking for options sweeps and dark pool activity on this name today and in the days ahead… I suspect Wall Street’s heaviest hitters will be buying into this one, if they haven’t already!

Let me know how you do today!

Yours for TrackStar trading,

Davis Martin
America’s #1 Premarket and Day Trader

Disclaimer: This is not investment advice. This article is for information purposes only and opinion-based on financial advisor data across a selection of websites. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions.